Risk assessment for therapeutic drugs

• US 9,927,443 B2
• Filed: 04/05/2016
• Issued: 03/27/2018
• Est. Priority Date: 04/10/2015
• Status: Active Grant

• Current Assignee: Conquerab Inc.
• Original Assignee: Conquerab Inc.
• Inventors: Barbosa, Maria D. F. S.
• Primary Examiner(s): Cheu, Changhwa J
• Application Number:
  US15/091,483
• Publication Number:
  US 20160320405A1
• Time in Patent Office: 721 Days
• Field of Search: None
• CPC Class Codes: A61B 5/145 Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissuemeasuring of blood pressure or blood flow A61B5/02; non-radiation detecting or locating of foreign bodies in blood A61B5/06
• CPC Class Codes: A61B 5/7275 Determining trends in physiological measurement data; Predicting development of a medical condition based on physiological measurements, e.g. determining a risk factor
• CPC Class Codes: G01N 33/54388 based on lateral flow
• CPC Class Codes: G01N 33/54391 based on vertical flow
• CPC Class Codes: G01N 33/558 using diffusion or migration of antigen or antibody immunochromatographic test strips G01N33/54387
• CPC Class Codes: G05B 15/00 Systems controlled by a computer G05B13/00, G05B19/00 take precedence; automatic controllers with particular characteristics G05B11/00
• CPC Class Codes: G06F 7/06 Arrangements for sorting, selecting, merging, or comparing data on individual record carriers
• CPC Class Codes: G16H 10/20 for electronic clinical trials or questionnaires
• CPC Class Codes: G16H 20/10 relating to drugs or medications, e.g. for ensuring correct administration to patients
• CPC Class Codes: Y02A 90/10 Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Abstract

Methods to estimate safety and/or efficacy of therapeutic drugs, which include portable devices for anti-drug antibody (ADA) testing and databases containing anonymized data from humans and/or animal models, and related analyses, are provided. These methods and compositions can be used in various applications, including but not restricted to the following: uniform testing of patients for ADA; selection of therapeutic drug for patient treatment; evaluation of the need to change therapeutic drug or to apply tolerance regimens; selection of patients for clinical trials; comparison of therapeutic drugs marketed for a given disease and also gene therapy; scientific guidance for discovering and/or developing therapeutic drugs; postmarketing surveillance of therapeutic drugs.

Claims

1. A method for assessing risks associated with human immune responses against therapeutic drugs, the method comprising:

a. Contacting a biological sample from a human subject with a portable device capable of testing for human anti-drug antibodies (ADAs) against one or more therapeutic drugs, wherein labeled entities are immobilized on the portable device, wherein said labeled entities on said device can bind to a constant region of the human ADAs and wherein the labeled entities bound to ADAs complex flow towards to one or more capture reagent immobilized on the device, and wherein the capture reagent comprises said therapeutic drugs or regions of said therapeutic drugs;

b. Detecting a visible signal resulting from binding of ADAs from step (a) to one or more therapeutic drugs or regions of said therapeutic drugs immobilized on the device; and

c. Correlating signal from step (b) with presence or absence of ADAs.

2. The method of claim 1, wherein a code on the portable device allows access to a database, and wherein the database comprises ADA data obtained from other human subjects, using the same portable device of claim 1.

3. The method of claim 2, wherein the database comprises genetic analyses of human patients, and their associations with human ADA responses or immune tolerance, and wherein ADA data used to test said associations comprise ADA data obtained with the portable device of claim 1.

4. The method of claim 2, wherein the database comprises data from human patients with one or more of the following:

autoimmune disease;

diabetes;

multiple sclerosis;

rheumatoid arthritis;

cancer;

cardiovascular disease;

other diseases for which treatment can include a therapeutic drug, wherein the drug is a protein or peptide, alone or conjugated with a chemical entity or moiety.

5. The method of claim 2, wherein the database contains information for one or more of the following therapeutic drugs:

insulin, native or modified;

interferon-β

, native or modified;

therapeutic antibody;

enzyme replacement therapy;

a therapeutic drug for other applications, wherein the drug is a protein or peptide, alone or conjugated with a chemical entity or moiety.

6. The method of claim 2, wherein the database is combined with other databases, and has differential levels of access and security.

7. The method of claim 2, wherein the database provides information for one or more of the following:

to assess the likelihood of host anti-drug antibody responses;

to assess likelihood of host neutralizing antibody responses;

to predict drug efficacy;

to predict drug safety;

to guide therapy selection;

to assess likelihood of adverse reactions upon administration of a therapeutic drug to a patient or animal model;

to estimate an effective therapeutic drug dose;

to obtain scientific guidance for engineering of biotherapeutics;

to engineer less immunogenic proteins;

to obtain scientific guidance for drug discovery;

to obtain scientific guidance for drug development;

for postmarketing surveillance of therapeutic drugs.

8. The method of claim 2, wherein the database contains ADA data obtained with said portable device, and comparisons with data obtained with other ADA assays.

9. The method of claim 2, wherein the database is used to compare therapeutic drugs and gene therapy within a given therapeutic area, wherein gene therapy comprises correction of a genetic defect in a human patient, and wherein the incidence of human ADAs against a therapeutic protein drug is compared with the incidence of human antibodies against the same protein following gene therapy.

10. The method of claim 2, wherein the database is used to evaluate therapeutic drugs, with analysis of patient megadata (big data), for applications including one or more of the following:

testing the effect of anti-drug antibodies and their possible associations with the etiology of diseases;

testing the influence of genetic components in ADA responses;

guiding discovery of novel therapeutic drugs;

guiding development of novel therapeutic drugs;

comparing therapeutic drugs for efficacy;

comparing therapeutic drugs for safety.

11. The method of claim 2, wherein the database provides guidance for therapeutic drug ranking and selection.